Free tool
FAERS Monitor: Lotrimin Ultra
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021307 or its brand name (Lotrimin Ultra, Butenafine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
578
Serious
61
11% of reports
Hospitalization
24
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective185
- off label use59
- product use issue43
- product use in unapproved indication34
- pruritus33
- condition aggravated29
- rash21
- drug ineffective for unapproved indication20
- drug effective for unapproved indication19
- erythema19
- drug effect decreased18
- product administered at inappropriate site15
- burning sensation12
- pain12
- product prescribing issue12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 41 |
| 2013 | 81 |
| 2014 | 61 |
| 2015 | 25 |
| 2016 | 31 |
| 2017 | 41 |
| 2018 | 42 |
| 2019 | 32 |
| 2020 | 28 |
| 2021 | 24 |
| 2022 | 27 |
| 2023 | 38 |
| 2024 | 30 |
| 2025 | 39 |
| 2026 | 29 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,581 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product administered at inappropriate siteSignal | 15 | 29.8 | 18.1 | 389 |
| drug effective for unapproved indicationSignal | 19 | 23.6 | 15.2 | 390 |
| product prescribing issueSignal | 12 | 20.1 | 11.5 | 199 |
| drug ineffective for unapproved indicationSignal | 20 | 13.3 | 8.6 | 215 |
| drug effect decreasedSignal | 18 | 12.2 | 7.7 | 174 |
| product use issueSignal | 43 | 8.3 | 6.2 | 272 |
| burning sensationSignal | 12 | 6.2 | 3.6 | 48 |
| drug ineffectiveSignal | 185 | 5.1 | 4.5 | 648 |
| product use in unapproved indicationSignal | 34 | 5.0 | 3.6 | 106 |
| condition aggravatedSignal | 29 | 3.5 | 2.4 | 49 |
| erythemaSignal | 19 | 3.4 | 2.2 | 30 |
| pruritusSignal | 33 | 3.1 | 2.2 | 46 |
| off label useSignal | 59 | 2.5 | 1.9 | 51 |
| rash | 21 | 1.8 | 1.2 | 6 |
| pain | 12 | 0.7 | 0.4 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.